文献速递眼底病与葡萄膜炎

未治疗新生血管性年龄相关性黄斑变性后黄斑萎缩的发生率:年龄相关性眼病研究第40号报告

Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 40.
PubMed 文献 · Ophthalmology · 2019-11-26

该研究基于AREDS前瞻性队列,纳入随访期间出现nAMD且未接受抗VEGF治疗的708只眼(627名参与者),评估后续黄斑萎缩的发生率。结果显示未治疗nAMD后黄斑萎缩累积风险2年9.6%、5年31.4%、7年43.1%、10年61.5%,对应线性年风险6.5%;对侧眼地理萎缩与黄斑萎缩风险增加相关(HR 1.70,95%CI 1.17-2.49,P=0.006),而AMD遗传风险评分及CFH、ARMS2、C3位点SNP无显著关联。

要点

  • 未治疗nAMD后黄斑萎缩累积风险2年9.6%、5年31.4%、7年43.1%、10年61.5%,线性年风险6.5%。
  • 对侧眼地理萎缩与黄斑萎缩风险增加相关(HR 1.70,95%CI 1.17-2.49,P=0.006)。
  • 黄斑萎缩中心受累在萎缩初现时占30.4%,2年43.4%,5年57.0%。

研究设计与样本

  • 研究为随机对照口服微量营养素补充试验中的前瞻性队列。
  • 纳入AREDS研究中55-80岁、随访期间(1992-2005)出现nAMD且未接受抗VEGF治疗的627名参与者共708只眼。
  • 每年研究访视采集彩色眼底照片并集中判读晚期AMD,采用Kaplan-Meier分析和比例风险回归评估nAMD后新发黄斑萎缩。

主要发现

  • 未治疗nAMD后黄斑萎缩累积风险2年9.6%(标准误1.2%)、5年31.4%(标准误2.2%)、7年43.1%(标准误2.6%)、10年61.5%(标准误4.3%)。
  • 黄斑萎缩对应线性年风险为6.5%。
  • 黄斑萎缩中心受累累积风险在萎缩初现时30.4%(标准误3.2%)、2年43.4%(标准误3.8%)、5年57.0%(标准误4.8%)。
  • 对侧眼地理萎缩与黄斑萎缩风险增加相关(HR 1.70,95%CI 1.17-2.49,P=0.006)。
  • 较高的52-SNP AMD遗传风险评分与黄斑萎缩风险增加无关(HR 1.03,95%CI 0.90-1.17,P=0.67),CFH、ARMS2或C3位点SNP亦无显著差异。

临床怎么用

  • 未治疗nAMD患者中黄斑萎缩随时间线性累积,约半数眼在8年时受累。
  • 对侧眼存在地理萎缩提示黄斑萎缩风险更高,应加强随访监测。
  • 除抗VEGF治疗外,自然进展至地理萎缩等因素也参与萎缩发生,解读治疗相关萎缩时需考虑此背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the natural history of untreated neovascular age-related macular degeneration (nAMD) regarding subsequent macular atrophy. DESIGN: Prospective cohort within a randomized, controlled trial of oral micronutrient supplements. PARTICIPANTS: Age-Related Eye Disease Study (AREDS) participants (55-80 years) who demonstrated nAMD during follow-up (1992-2005), prior to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Color fundus photographs were collected at annual study visits and graded centrally for late age-related macular degeneration (AMD). Incident macular atrophy after nAMD was examined by Kaplan-Meier analysis and proportional hazards regression. MAIN OUTCOME MEASURES: Incident macular atrophy after nAMD. RESULTS: Of the 4757 AREDS participants, 708 eyes (627 participants) demonstrated nAMD during follow-up and were eligible. The cumulative risks of incident macular atrophy after untreated nAMD were 9.6% (standard error, 1.2%), 31.4% (standard error, 2.2%), 43.1% (standard error, 2.6%), and 61.5% (standard error, 4.3%) at 2, 5, 7, and 10 years, respectively. This corresponded to a linear risk of 6.5% per year. The cumulative risk of central involvement was 30.4% (standard error, 3.2%), 43.4% (standard error, 3.8%), and 57.0% (standard error, 4.8%) at first appearance of atrophy, 2 years, and 5 years, respectively. Geographic atrophy (GA) in the fellow eye was associated with increased risk of macular atrophy (hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.17-2.49; P = 0.006). However, higher 52-single nucleotide polymorphism AMD genetic risk score was not associated with increased risk of macular atrophy (HR, 1.03; 95% CI, 0.90-1.17; P = 0.67). Similarly, no significant differences were observed according to SNPs at CFH, ARMS2, or C3. CONCLUSIONS: The rate of incident macular atrophy after untreated nAMD is relatively high, increasing linearly over time and affecting half of eyes by 8 years. Hence, factors other than anti-VEGF therapy are involved in atrophy development, including natural progression to GA. Comparison with studies of treated nAMD suggests it may not be necessary to invoke a large effect of anti-VEGF therapy on inciting macular atrophy, although a contribution remains possible. Central involvement is present in one third of eyes at the outset (similar to pure GA) and increases linearly to half at 3 years.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Christakis PG, Agrón E, Klein ML, et al. Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 40. Ophthalmology. 2019. PMID: 31899035. doi:10.1016/j.ophtha.2019.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。